File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Clinical Therapeutics in Hong Kong

TitleClinical Therapeutics in Hong Kong
Authors
KeywordsClinical trials
Hong Kong
Pharmaceutical inspection cooperation scheme
Therapeutics
Issue Date2019
PublisherExcerpta Medica, Inc. The Journal's web site is located at http://www.elsevier.com/locate/clinthera
Citation
Clinical Therapeutics, 2019, v. 41 n. 3, p. 592-597 How to Cite?
AbstractHong Kong is a compact territory in Southern China that enjoys a high degree of autonomy. Despite its dense population and uneven wealth distribution, infant mortality is low and life expectancy is long. The health service is more hospital and clinic based than community based. This seems cost-effective while professional standards are high and rigorously maintained. Drug registration follows American and European requirements. Hong Kong is a part of the Pharmaceutical Inspection Cooperation Scheme, which brings a high standard of drug regulation. Hong Kong is a good choice for clinical trials because the subjects are Chinese and protocols in English do not need to be translated. There are also 2 well-established clinical trials centers in university hospitals that also run Phase I and clinical pharmacology studies.
Persistent Identifierhttp://hdl.handle.net/10722/273954
ISSN
2023 Impact Factor: 3.2
2023 SCImago Journal Rankings: 0.875
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorCheung, BMY-
dc.contributor.authorYau, HKC-
dc.date.accessioned2019-08-18T14:52:05Z-
dc.date.available2019-08-18T14:52:05Z-
dc.date.issued2019-
dc.identifier.citationClinical Therapeutics, 2019, v. 41 n. 3, p. 592-597-
dc.identifier.issn0149-2918-
dc.identifier.urihttp://hdl.handle.net/10722/273954-
dc.description.abstractHong Kong is a compact territory in Southern China that enjoys a high degree of autonomy. Despite its dense population and uneven wealth distribution, infant mortality is low and life expectancy is long. The health service is more hospital and clinic based than community based. This seems cost-effective while professional standards are high and rigorously maintained. Drug registration follows American and European requirements. Hong Kong is a part of the Pharmaceutical Inspection Cooperation Scheme, which brings a high standard of drug regulation. Hong Kong is a good choice for clinical trials because the subjects are Chinese and protocols in English do not need to be translated. There are also 2 well-established clinical trials centers in university hospitals that also run Phase I and clinical pharmacology studies.-
dc.languageeng-
dc.publisherExcerpta Medica, Inc. The Journal's web site is located at http://www.elsevier.com/locate/clinthera-
dc.relation.ispartofClinical Therapeutics-
dc.subjectClinical trials-
dc.subjectHong Kong-
dc.subjectPharmaceutical inspection cooperation scheme-
dc.subjectTherapeutics-
dc.titleClinical Therapeutics in Hong Kong-
dc.typeArticle-
dc.identifier.emailCheung, BMY: mycheung@hkucc.hku.hk-
dc.identifier.emailYau, HKC: kcyau@hku.hk-
dc.identifier.authorityCheung, BMY=rp01321-
dc.description.naturepostprint-
dc.identifier.doi10.1016/j.clinthera.2019.01.002-
dc.identifier.pmid30709611-
dc.identifier.scopuseid_2-s2.0-85060658729-
dc.identifier.hkuros302281-
dc.identifier.volume41-
dc.identifier.issue3-
dc.identifier.spage592-
dc.identifier.epage597-
dc.identifier.isiWOS:000464625500018-
dc.publisher.placeUnited States-
dc.identifier.issnl0149-2918-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats